Aktuellt
SENASTE
Since our initiation of coverage, Nexstim has continued to deliver solid and higher-than-expected growth in its key segments of diagnostics and therapeutics. We take a more positive stance on Nexstim and increase our valuation to SEK 65 (60) – representing upside of roughly 40 percent. We slightly lift our near-term growth expectations for the key diagnostics and depression therapy segments (NBS and NBT), assigning a CAGR of 27% in the upcoming five years, as well as our estimation of profitability.
LÄS MER
